Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: MAIA )

2.150 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about MAIA

< Previous 1 2 3 Next >
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits 
Via News Direct
MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q2 2024
MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
MAIA Biotechnology's Phase 2 THIO-101 trial shows promising updates for THIO with Regeneron's cemiplimab in advanced NSCLC patients. Results include a 38% ORR, 85% DCR, and lower toxicity, with six... 
Via Benzinga
Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
New Clinical Data Reveals MAIA Biotechnology's THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment
--News Direct-- 
Via News Direct
Topics Death
Exposures Death
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
MAIA Biotechnology's Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market
MAIA Biotechnology's Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market 
Via News Direct
MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q1 2024
MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q4 2023
MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
MAIA Biotech Completes Enrollment For Phase 2 Trial Of Its Candidate THIO To Fight Non-Small Cell Lung Cancer
--News Direct-- 
Via News Direct
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
Novel Therapy Shows Promising Results In On-Going Trials, Receives 3 Orphan Drug Designations From The FDA
Vlad Vitoc, MD, MBA; CEO & Chairman of MAIA Biotechnology (NYSE: MAIA), was a guest on Benzinga’s All Access. MAIA is a targeted therapy immuno-oncology company focused on developing and... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Wipro Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Wipro Limited (NYSE: WIT) rose sharply during Friday’s session after the company reported third-quarter financial results, issued guidance and declared an interim dividend. Wipro shares... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why VCI Global Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket
Shares of VCI Global Limited (NASDAQ: VCIG) fell sharply in pre-market trading after the company announced pricing of $2.75 million public offering. VCI Global shares tumbled 29.5% to $1.10 in... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting out the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
What's Going On With Crispr Therapeutics Stock Thursday?
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Thursday after the company announced regulatory authorization of the first CRISPR/Cas9 gene- 
Via Benzinga
MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer
More than 300,000 people are diagnosed with brain cancer across the globe each year. 
Via Benzinga
Exposures Product Safety
Why MAIA Biotechnology Stock Is Nosediving During Wednesday's Session
MAIA Biotechnology Inc (NASDAQ: MAIA) shares are trading lower by 20.97% to $1.47 Wednesday morning after the company announced it's finalizing a deal to sell about 2.4 million shares of its common... 
Via Benzinga
MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer
New results from a targeted therapy and immuno-oncology company show the promising potential efficacy of one of its first-in-class treatments.  
Via Benzinga
MAIA Biotechnology's THIO Emerges As Potential Breakthrough In Pediatric Brain Cancer Therapy
Diffuse Intrinsic Pontine Glioma (DIPG) is among the most aggressive brain tumors affecting the central nervous system in children. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.